fluoxetine has been researched along with Liver Diseases in 4 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Liver Diseases: Pathological processes of the LIVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fluoxetine has a nonlinear pharmacokinetic profile." | 2.39 | Clinical pharmacokinetics of fluoxetine. ( Altamura, AC; Moro, AR; Percudani, M, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (75.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bobo, WV | 1 |
| Shelton, RC | 1 |
| Altamura, AC | 1 |
| Moro, AR | 1 |
| Percudani, M | 1 |
| Bergstrom, RF | 1 |
| Beasley, CM | 1 |
| Levy, NB | 1 |
| Blumenfield, M | 1 |
| Lemberger, L | 1 |
| Lin, X | 1 |
| Levitsky, DA | 1 |
| King, JM | 1 |
| Campbell, TC | 1 |
3 reviews available for fluoxetine and Liver Diseases
| Article | Year |
|---|---|
Efficacy, safety and tolerability of Symbyax for acute-phase management of treatment-resistant depression.
Topics: Adult; Age Factors; Antidepressive Agents; Benzodiazepines; Depression; Drug Combinations; Drug Inte | 2010 |
Clinical pharmacokinetics of fluoxetine.
Topics: Administration, Oral; Aged; Aging; Biological Availability; Dose-Response Relationship, Drug; Drug I | 1994 |
The effects of renal and hepatic disease on the pharmacokinetics, renal tolerance, and risk-benefit profile of fluoxetine.
Topics: Adult; Aged; Clinical Trials as Topic; Depressive Disorder; Dose-Response Relationship, Drug; Drug A | 1993 |
1 other study available for fluoxetine and Liver Diseases
| Article | Year |
|---|---|
The promotion effect of anorectic drugs on aflatoxin B(1)-induced hepatic preneoplastic foci.
Topics: Adipose Tissue, Brown; Aflatoxin B1; Amphetamine; Animals; Appetite Depressants; Biomarkers; Body Te | 1999 |